IgA Nephropathy Study
If you or a loved one suffers from IgA Nephropathy, a clinical study may be able to help.
Who’s Included?
Adults; All genders
18–65
Drug & Formulation
BHVN-1400
Other
Possibility of Placebo
What is IgA Nephropathy (IgAN)?
IgAN is the most common type of kidney inflammation worldwide. It is usually found in people between the ages of 20 and 40 and often shows up as blood or protein in the urine. About 30–40% of people with IgAN may develop serious kidney disease 20 to 30 years after first showing symptoms. IgAN happens when the body makes too much of a substance called Gd-IgA1. The immune system reacts by making antibodies that stick to it, forming clumps that build up in the kidneys. This buildup causes scarring and inflammation, which can damage the kidneys over time and may lead to kidney failure. Right now, there are no approved treatments that directly target the root cause, Gd-IgA1.
- Participants must have biopsy-confirmed IgA Nephropathy.
- Any secondary IgAN
- Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause
Learn more about the benefits of joining our trial and see if you qualify today!
Frequently Asked Questions
About 10 people will participate in this study.
This study is being conducted on behalf of Biohaven by multiple sites (clinics or hospitals) across the United States and the UK, with trained and qualified medical specialists.
No. If you qualify and are chosen to participate, you will receive all study-related care at no cost to you.
Your participation is fully voluntary. You may leave the study at any time
Visit the See If You Qualify page if you are interested in participating in this study. Find a clinic near you on the map ,and fill out the form. A qualified clinician will follow up with you to discuss your potential enrollment in the study.